Automated Nucleated Red Blood Cell Enumeration Evaluated
|
By LabMedica International staff writers Posted on 17 Jun 2015 |
The enumeration of nucleated red blood cell (NRBC) has been evaluated on a new automated hematology analyzer and to demonstrate the precision compared to manual counts (MC) at the various NRBC values.
The presence of peripheral blood nucleated red blood cell is associated with pathological conditions and leads to the overestimation of white blood cell count in automated hematology analyzers (HA) and therefore, accurate detection and enumeration of NRBCs are important.
Scientists at Mahidol University (Bangkok, Thailand) analyzed clinical blood specimens that were sent from both in- and out-patient departments to a central laboratory at during August 2013 and October 2013. These peripheral blood specimens were collected using dipotassium ethylenediaminetetraacetic acid (EDTA) as an anticoagulant. The residual samples from routine testing with adequate volume for repeated testing were used and were analyzed within two hours of blood collection.
The automated hematology analyzer used was the Sysmex XN-3000 (Sysmex Corporation; Kobe, Japan) which comprises one sampler, two Sysmex XN Modular analyzers, and one Sysmex SP-10 slidemaker/stainer. Blood smears were prepared on the Sysmex SP-10 slidemaker/stainer using Wright-Giemsa reagent. Staff member counted the number of NRBCs per 200 white blood cells (WBCs) using light microscope at × 400 magnification. Included in the study were 234 specimens from 127 patients (54 males and 73 females) with initial reports of NRBCs more than 0.1% by automated hematology analyzer.
In the comparison study between XN and MC, NRBCs ranged from 0% to 612.5%. Regression analysis demonstrated a close accord between the methods. The mean bias of 14.1% with 95% limits of agreement between 48.76% and 76.95% was found. The NRBC counts from XN appeared to be more in accordance with MC when the NRBCs were lower than 200% with the concordance rate of 94.2%.
The authors concluded that the automated NRBC enumeration by XN was precise and could replace the traditional MC, especially for the specimens with NRBCs lower than 200%. This approach may improve laboratory management, especially for laboratories which frequently encounter normoblastemia. It should be noted that MC is a very laborious procedure requiring skilled technical knowledge. The study was published in the June 2015 issue of the International Journal of Laboratory Hematology.
Related Links:
Mahidol University
Sysmex Corporation
The presence of peripheral blood nucleated red blood cell is associated with pathological conditions and leads to the overestimation of white blood cell count in automated hematology analyzers (HA) and therefore, accurate detection and enumeration of NRBCs are important.
Scientists at Mahidol University (Bangkok, Thailand) analyzed clinical blood specimens that were sent from both in- and out-patient departments to a central laboratory at during August 2013 and October 2013. These peripheral blood specimens were collected using dipotassium ethylenediaminetetraacetic acid (EDTA) as an anticoagulant. The residual samples from routine testing with adequate volume for repeated testing were used and were analyzed within two hours of blood collection.
The automated hematology analyzer used was the Sysmex XN-3000 (Sysmex Corporation; Kobe, Japan) which comprises one sampler, two Sysmex XN Modular analyzers, and one Sysmex SP-10 slidemaker/stainer. Blood smears were prepared on the Sysmex SP-10 slidemaker/stainer using Wright-Giemsa reagent. Staff member counted the number of NRBCs per 200 white blood cells (WBCs) using light microscope at × 400 magnification. Included in the study were 234 specimens from 127 patients (54 males and 73 females) with initial reports of NRBCs more than 0.1% by automated hematology analyzer.
In the comparison study between XN and MC, NRBCs ranged from 0% to 612.5%. Regression analysis demonstrated a close accord between the methods. The mean bias of 14.1% with 95% limits of agreement between 48.76% and 76.95% was found. The NRBC counts from XN appeared to be more in accordance with MC when the NRBCs were lower than 200% with the concordance rate of 94.2%.
The authors concluded that the automated NRBC enumeration by XN was precise and could replace the traditional MC, especially for the specimens with NRBCs lower than 200%. This approach may improve laboratory management, especially for laboratories which frequently encounter normoblastemia. It should be noted that MC is a very laborious procedure requiring skilled technical knowledge. The study was published in the June 2015 issue of the International Journal of Laboratory Hematology.
Related Links:
Mahidol University
Sysmex Corporation
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Hematology News
- New Guidelines Aim to Improve AL Amyloidosis Diagnosis
- Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
- Fast and Easy Test Could Revolutionize Blood Transfusions
- High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
- AI Algorithm Effectively Distinguishes Alpha Thalassemia Subtypes
- MRD Tests Could Predict Survival in Leukemia Patients
- Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
- Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
- ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
- Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
- Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
- Platelets Could Improve Early and Minimally Invasive Detection of Cancer
- Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
- Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
- First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes

- New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more








